Dr. Hamza Hashmi

Hamza Hashmi, MD, is a hematologist-oncologist specializing in the care of patients with multiple myeloma and other plasma cell disorders. He focuses on treating both newly diagnosed and relapsed myeloma, bringing expertise across a range of therapeutic approaches including chemotherapy, bone marrow transplantation, and chimeric antigen receptor (CAR) T cell therapy. His clinical practice is guided by a commitment to compassion, empathy, competence, and personalized care, with a philosophy that myeloma treatment is a long-term journey rather than a short-term effort. He places strong emphasis on collaborative decision-making, drawing on each patient's hopes, goals, and preferences to shape their individualized treatment plan.

Dr. Hashmi is actively involved in developing new therapies for multiple myeloma through clinical trials, with a particular focus on novel chemotherapy and immunotherapy approaches including CAR T cell therapy and bispecific antibodies. His research also explores the complex relationship between cancer biology and the immune system, aiming to better understand and overcome treatment resistance in myeloma. By connecting laboratory insights to clinical application, he works to expand the therapeutic options available to patients with relapsed or refractory disease.

Outside of his clinical and research work, Dr. Hashmi recognizes the profound impact a blood cancer diagnosis has not only on patients but on their entire families, and he takes pride in supporting individuals at every stage of their care. He is known for listening closely to his patients and incorporating their voices meaningfully into treatment decisions. Away from medicine, he pursues amateur photography as a creative outlet, finding in it another way to observe and narrate the world around him.